Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 11/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4107181 | 0.91 | HRH3 (0.48) | VCPIRAK4HRH3FGFR1KDR | |
| SCHEMBL4108114 | 0.90 | HRH3 (0.50) | VCPIRAK4HRH3FGFR1KDR | |
| SCHEMBL4115467 | 0.90 | VCP (0.37) | VCPIRAK4IRAK1 | |
| SCHEMBL4101575 | 0.90 | VCP (0.41) | VCPIRAK4HRH3 | |
| SCHEMBL4107222 | 0.90 | VCP (0.53) | VCPIRAK4HRH3FGFR1KDR | |
| SCHEMBL4112193 | 0.90 | VCP (0.49) | VCPIRAK4HRH3FGFR1KDR | |
| SCHEMBL4082906 | 0.89 | VCP (0.54) | VCPIRAK4IRAK1 | |
| SCHEMBL4108348 | 0.88 | VCP (0.44) | VCPIRAK4HRH3FGFR1KDR | |
| SCHEMBL4101571 | 0.85 | VCP (0.40) | VCPIRAK4 | |
| SCHEMBL4112439 | 0.84 | VCP (0.40) | VCPIRAK4HRH3IRAK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | claimed |
| US-8354407-B2 | 2-anilino-4-(heterocyclic)amino-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | VCP 930/4885IRAK4 1916/4885HRH3 3345/4885 |
| US-20090227586-A1 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES | PRKCA, PRKCG, PRKCH | VCP 930/4885IRAK4 1916/4885HRH3 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.